All studies
AuthorisedTherapeutic confirmatory (Phase III)Interventional

VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Gedatolisib with Endocrine Therapy and Palbociclib vs Endocrine Therapy and Ribociclib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

The VIKTORIA-2 study is a phase 3 clinical trial for adults with hormone receptor-positive (HR-positive) and HER2-negative advanced breast cancer. This type of cancer is fueled by hormones like estrogen and does not have high levels of the HER2 protein. Doctors want to find out if adding an experimental medicine called gedatolisib to standard cancer treatments helps control the disease for longer. Standard treatments include hormone therapy (such as letrozole or fulvestrant) combined with targeted drugs called CDK4/6 inhibitors (such as palbociclib or ribociclib). Participants will be placed into treatment groups to compare the new drug combination against the current standard of care. Because this is for first-line treatment, it is open to people who have not yet received medicine for their advanced breast cancer. The trial will help doctors understand if this new combination is both safe and more effective.

At a glance

What is this study about?

Breast cancer is often described by the specific proteins or receptors found on the cancer cells. In HR-positive, HER2-negative breast cancer, the cells grow in response to hormones such as estrogen, but they do not have high amounts of a protein called HER2. When this type of cancer spreads to other parts of the body or cannot be removed with surgery, doctors call it advanced breast cancer. The usual first step in treatment involves medicines that block hormones, combined with targeted drugs known as CDK4/6 inhibitors that slow down cell division.

While these standard treatments can work very well for a long time, cancer cells can eventually find ways around them and start growing again. Researchers are testing whether adding a new targeted medicine, called gedatolisib, can block other growth signals inside the cancer cells. By blocking multiple pathways at the same time, doctors hope to keep the cancer under control for a longer period.

The VIKTORIA-2 trial compares standard treatment combinations against a combination that includes gedatolisib. It will look at people whose cancer is still sensitive to hormone therapy, as well as those whose cancer may have become resistant to past hormone treatments. The results will help doctors decide whether this new combination should become a new standard treatment option in the UK and worldwide.

Key takeaways

  • A phase 3 clinical trial testing a new combination treatment for advanced breast cancer.
  • Aimed at adults with HR-positive, HER2-negative advanced breast cancer who have not had prior treatment for advanced disease.
  • Compares the new drug gedatolisib plus standard therapy against standard therapy alone.
  • Involves regular hospital visits for medication, blood tests, and scans.
  • Participation is completely voluntary and you may withdraw at any time.

Who may be eligible?

This trial is for adults aged 18 and older who have been diagnosed with advanced breast cancer that is HR-positive and HER2-negative. Advanced cancer means it has either spread to other areas of the body (secondary or metastatic cancer) or has grown locally and cannot be removed by an operation.

To take part, you must not have received any previous drug treatments (such as chemotherapy or targeted therapy) for your advanced breast cancer. The study is split into groups depending on how your cancer previously responded to hormone treatments, covering both people whose cancer seems sensitive to hormone therapy and those whose cancer may be resistant.

Your general health, organ function, and medical history will also be reviewed by the trial team. People who have had certain other medical conditions or specific past treatments may not be able to join. Your cancer doctor will do detailed checks, including scans and blood tests, to see if the trial is a safe match for you.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or older.
  2. I have been diagnosed with advanced or metastatic breast cancer.
  3. My cancer has tested HR-positive and HER2-negative.
  4. I have not yet started drug treatment for this advanced stage of cancer.
  5. I am able and willing to attend regular hospital visits for scans, blood tests, and check-ups.
Answer every question to see your result.

What does participation involve?

If you decide to take part, you will be assigned by chance (randomised) to one of the study treatment groups. Depending on your group, you will receive either the new drug combination including gedatolisib along with standard medicines, or standard medicines alone (such as ribociclib or palbociclib combined with letrozole or fulvestrant). Treatments are given either as tablets to swallow at home or as injections and infusions at the hospital clinic.

You will need to visit the hospital regularly for check-ups. These visits will include blood tests, physical examinations, and questions about how you are feeling. You will also have regular imaging scans, such as CT or MRI scans, to see how the cancer is responding to treatment.

You can continue taking the study medication for as long as it is helping to keep your cancer stable and you are not having difficult side effects. After treatment finishes, the study team will continue to check on your health and well-being through routine clinic visits or phone calls.

Potential risks and benefits

Taking part in this study may help keep your cancer under control for longer, and the findings could help improve care for future patients. However, there is no guarantee of direct personal benefit. Like all cancer medicines, the drugs used in this trial can cause side effects. These may include feeling tired, sickness, mouth sores, changes in blood counts, or higher risks of infection. Your study team will monitor you very closely to manage any symptoms quickly. Taking part is completely voluntary. You are free to leave the trial at any time without giving a reason, and your regular NHS medical care will not be affected.

Locations (14)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Finland
  • —
    Unverified
    Bulgaria
  • —
    Unverified
    Portugal
  • —
    Unverified
    Germany
  • —
    Unverified
    Greece
  • —
    Unverified
    Romania
  • —
    Unverified
    Poland
  • —
    Unverified
    Hungary
  • —
    Unverified
    Czechia
  • —
    Unverified
    Italy
  • —
    Unverified
    Denmark
  • —
    Unverified
    Belgium

Common questions

What is the main goal of the VIKTORIA-2 trial?

The study aims to see if adding the experimental drug gedatolisib to standard targeted and hormone therapies helps keep advanced breast cancer from growing for longer than standard care alone.

Can I choose which treatment I receive?

No. A computer system assigns participants to a treatment group at random. This makes sure the comparison between treatments is scientifically fair and unbiased.

Will I have to pay for the trial treatments?

No. The trial medication is provided free of charge. In many cases, travel expenses to and from hospital visits may also be covered by the study.

What happens if I experience unpleasant side effects?

Your study team will check on you regularly. If you have side effects, your doctor can lower your dose, temporarily pause the medicine, or give you treatments to relieve your symptoms.

Can I leave the study if I change my mind?

Yes. You can leave the study at any point. Your decision will not affect the quality of your regular NHS care or your relationship with your medical team.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.